[Fenigidin in the treatment of patients with chronic cholecystitis in combination with chronic ischemic heart disease].
A study is presented of 58 patients with chronic cholecystitis associated with chronic ischemic heart disease. Single sublingual use of phenigidin was followed by ultrasonic examination and revealed elimination of signs of spasm of the sphincter apparatus of the biliary tract and improvement of evacuation of bile from the gallbladder. Peroral use of phenigidin (10-20 mg three times daily before meals for 2-3 weeks) was accompanied by a positive dynamics of clinical manifestations of chronic cholecystitis and chronic ischemic heart disease. Average indices of tolerance to physical loads (bicycle ergometric [correction of veloergometric] data) did not change essentially as a result of treatment.
Kushnir
V E
VE
Dynnik
O B
OB
Sidorova
L L
LL
Kuklia
Iu S
IuS
D000286:Administration, Sublingual; D001659:Biliary Tract / Q000473:pathology; D002764:Cholecystitis / Q000175:diagnosis / Q000188:drug therapy*; D002908:Chronic Disease; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy*; D004341:Drug Evaluation; D005080:Exercise Test; D006801:Humans; D009543:Nifedipine / Q000627:therapeutic use*; D010807:Physical Endurance / Q000187:drug effects; D014463:Ultrasonography
D009543:Nifedipine
Fenigidin v lechenii bol'nykh khronicheskim kholetsistitom v sochetanii s khronicheskoĭ ishemicheskoĭ bolezn'iu serdtsa.